Physician profile
Lucia E Gilling
NPI 1174517247
$4,643.62
in general payments reported to CMS, 2019-2025
30 companies · $706 in 2025
The $706 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $718 · 2021: $146 · 2022: $692 · 2023: $1,003 · 2024: $814 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,481 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,481.02 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $854.79 | 2019-2025 | |
| Mannkind Corporation | $601.16 | 2019-2025 | Afrezza |
| Lilly USA, LLC | $575.25 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $285.54 | 2019-2025 | Evenity, Tepezza |
| Novo Nordisk INC | $238.33 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $208.79 | 2019-2022 | |
| Ibsa Pharma INC. | $201.74 | 2019-2025 | Tirosint, Tirosint, Licart |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.89 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $185.69 | 2019-2023 | Steglatro, Steglujan |
| Bayer Healthcare Pharmaceuticals INC. | $168.64 | 2024-2025 | |
| Abbott Laboratories | $158.78 | 2019-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $141.22 | 2020-2023 | Dexcom G6 Transmitter |
| Amryt Pharma Holdings LTD | $121.95 | 2023 | Mycapssa |
| Intuity Medical INC | $102.65 | 2022 | |
| Insulet Corporation | $90.47 | 2019-2025 | Omnipod |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $76.17 | 2022-2025 | Minimed 780g |
| Amneal Pharmaceuticals LLC | $57.05 | 2019-2025 | Unithroid |
| Radius Health, INC. | $55.91 | 2020-2023 | Tymlos |
| Ascendis Pharma Endocrinology INC | $53.34 | 2025 | Yorvipath |
| Medtronic Minimed, INC. | $53.06 | 2019-2020 | |
| Abbvie INC. | $32.08 | 2021-2023 | |
| Sequel Med Tech, LLC | $29.75 | 2025 | Twiist |
| Beta Bionics, INC. | $21.91 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Acella Pharmaceuticals, LLC | $21.03 | 2022 | |
| Cequr Corporation | $20.33 | 2023 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $19.50 | 2023 | Gvoke Hypopen |
| Valeritas, INC. | $19.40 | 2019 | |
| Zealand Pharma US, INC. | $19.11 | 2020 | |
| Antares Pharma, INC. | $16.74 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucia Gilling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.